captopril has been researched along with Weight Gain in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH; Kim, SH; Oh, YB; Park, BH; Park, BM | 1 |
| Bastani, B; Redington, J | 1 |
| Akçiçek, F; Asci, G; Gürgün, C; Mees, EJ; Ozerkan, F; Ozkahya, M; Töz, H; Unsal, A | 1 |
| Howard, EF; Landon, EJ; Myers, PR; Steimle, A; Takagi, T; Tamura, M; Tanner, M | 1 |
2 trial(s) available for captopril and Weight Gain
| Article | Year |
|---|---|
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Glucose; Captopril; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Female; Follow-Up Studies; Humans; Hypertension; Hypoglycemia; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Peripheral Vascular Diseases; Prospective Studies; Proteinuria; Visual Acuity; Weight Gain | 1998 |
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Captopril; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemia; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Peripheral Vascular Diseases; Prospective Studies; Treatment Outcome; Visual Acuity; Weight Gain | 1998 |
4 other study(ies) available for captopril and Weight Gain
| Article | Year |
|---|---|
Captopril intake decreases body weight gain via angiotensin-(1-7).
Topics: Adipocytes; Adipose Tissue; Adiposity; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cell Size; Cells, Cultured; Epididymis; Glycerol; Lipolysis; Male; Peptide Fragments; Primary Cell Culture; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Sterol Esterase; Weight Gain | 2012 |
Lack of efficacy of angiotensin-converting enzyme inhibitors in reducing interdialytic weight gain.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Captopril; Enalapril; Fosinopril; Humans; Hypertension; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Retrospective Studies; Weight Gain | 1994 |
Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Captopril; Cardiomegaly; Diet, Sodium-Restricted; Female; Hemodiafiltration; Humans; Hypertension; Male; Middle Aged; Radiography, Thoracic; Renal Dialysis; Retrospective Studies; Time Factors; Weight Gain | 1999 |
Induction of angiotensin II subtype 2 receptor-mediated blood pressure regulation in synthetic diet-fed rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Captopril; Cardiac Glycosides; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epinephrine; Gene Expression; Imidazoles; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Norepinephrine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Signal Transduction; Vasoconstrictor Agents; Vasodilation; Weight Gain | 2000 |